Comparison of Treatment Approaches for Relapse of T-Cell Leukemia in Children: Block Therapy Versus Continuous Chemotherapy

T-cell acute lymphoblastic leukemia (T-ALL) is a rapidly progressing, aggressive form of blood cancer in which immature T cells (a subtype of white blood cells) grow uncontrollably in the bone marrow. These cancer cells displace the healthy bone marrow, preventing it from producing enough functional blood cells. As a result, patients often experience infections, bleeding, general weakness, or shortness of breath. T-ALL belongs to the group of acute lymphoblastic leukemias (ALL) and, although it occurs less frequently than the B-cell variant, carries a higher risk of relapse. Despite good chances of cure with initial treatment, some patients experience a relapse. In these cases, renewed, usually intensive therapy is necessary, aimed at a complete cure (curative). In the event of a relapse, the so-called R-block therapy is usually used—an intensive treatment consisting of several chemotherapy blocks. Between treatment phases, the children are given time to recover physically. A key factor in further planning is what is known as minimal residual disease (MRD)—that is, the number of cancer cells still detectable in the body after the initial therapy. If the MRD is elevated or the patient is considered high-risk, an additional stem cell transplant is generally recommended. In addition to this standard therapy, the study investigated an alternative method: continuous, lower-dose chemotherapy (consolidation therapy), in which the drugs are administered evenly over a longer period of time. The goal was to reduce the physical strain and side effects without compromising efficacy.

The goal of this Phase 4 study was to identify the most effective and, at the same time, best-tolerated form of therapy for relapsed T-cell ALL and related T-cell lymphoblastic disorders in children and adolescents. It was not designed to approve new drugs, but rather to compare already known and proven active ingredients in different treatment regimens. To this end, patients who had experienced a relapse first underwent intensive initial treatment (reinduction therapy) and were subsequently randomly assigned to one of two treatment arms. In one arm, further treatment consisted of the established, block-based chemotherapy (R-block therapy); in the other, continuous, less intensively dosed chemotherapy. Concurrently, treatment response (MRD), long-term survival, and side effects were systematically recorded to directly compare the efficacy and tolerability of the two approaches. The patients were monitored as part of the study over several years until the study’s conclusion in 2012. The study showed that both therapies were comparably effective, but that continuous therapy resulted in fewer side effects. Therefore, it was recommended as the new standard of care.

Children and adolescents up to age 18 who had been definitively diagnosed with a relapse of T-cell acute lymphoblastic leukemia (T-ALL) or a related T-cell lymphoblastic lymphoma were eligible to participate.